Eric Warren Sells 7,437 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) insider Eric Warren sold 7,437 shares of the stock in a transaction on Friday, August 21st. The stock was sold at an average price of $25.98, for a total value of $193,213.26. Following the transaction, the insider owned 38,400 shares of the company’s stock, valued at approximately $997,632. This represents a 16.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Eric Warren also recently made the following trade(s):

• On Tuesday, July 21st, Eric Warren sold 7,438 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $26.87, for a total transaction of $199,859.06.
• On Friday, June 26th, Eric Warren sold 104,124 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $25.90, for a total transaction of $2,696,811.60.

Mineralys Therapeutics Trading Down 1.7%

Shares of MLYS stock opened at $25.89 on Thursday. The company has a debt-to-equity ratio of 0.18, a current ratio of 34.46 and a quick ratio of 34.46. The firm has a market cap of $2.29 billion, a PE ratio of -6.11 and a beta of 0.68. The company has a 50-day moving average of $26.83 and a two-hundred day moving average of $27.21. Mineralys Therapeutics, Inc. has a 1-year low of $14.94 and a 1-year high of $47.65.

Mineralys Therapeutics (NASDAQ:MLYS) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($2.85) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($2.30). On average, analysts predict that Mineralys Therapeutics, Inc. will post -4.45 EPS for the current year.

Institutional Investors Weigh In On Mineralys Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. purchased a new stake in shares of Mineralys Therapeutics during the second quarter worth $158,832,000. State Street Corp boosted its holdings in Mineralys Therapeutics by 144.4% in the fourth quarter. State Street Corp now owns 3,184,999 shares of the company’s stock valued at $115,584,000 after purchasing an additional 1,881,976 shares during the period. California State Teachers Retirement System grew its stake in Mineralys Therapeutics by 2,860.2% during the 2nd quarter. California State Teachers Retirement System now owns 1,813,623 shares of the company’s stock worth $48,932,000 after purchasing an additional 1,752,357 shares in the last quarter. Bank of America Corp DE purchased a new stake in Mineralys Therapeutics during the 2nd quarter worth about $40,620,000. Finally, Price T Rowe Associates Inc. MD increased its holdings in Mineralys Therapeutics by 6,097.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,325,120 shares of the company’s stock worth $48,089,000 after purchasing an additional 1,303,737 shares during the period. 84.46% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have commented on MLYS. Jefferies Financial Group restated a “hold” rating on shares of Mineralys Therapeutics in a research note on Monday, June 1st. HC Wainwright reaffirmed a “buy” rating on shares of Mineralys Therapeutics in a research note on Monday, June 1st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Mineralys Therapeutics in a report on Friday, July 17th. Wall Street Zen lowered Mineralys Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 15th. Finally, Zacks Research cut Mineralys Therapeutics from a “hold” rating to a “strong sell” rating in a report on Thursday, August 13th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $49.33.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.